Long Island City, NY, United States of America

Thomas P Cirrito

USPTO Granted Patents = 4 

 

 

Average Co-Inventor Count = 2.7

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2019-2025

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Thomas P. Cirrito: Innovator in Cancer Vaccine Development

Introduction

Thomas P. Cirrito is a notable inventor based in Long Island City, NY (US). He has made significant contributions to the field of cancer research, particularly in the development of targeted cancer vaccines. With a total of 4 patents to his name, Cirrito's work is paving the way for innovative treatments in oncology.

Latest Patents

Cirrito's latest patents focus on cancer stem cell targeted cancer vaccines. These patents provide methods for treating and vaccinating against cancer. They include regimens for administering these vaccines, which comprise peptides, compositions, immunomodulatory agents, and emulsifiers. Additionally, the patents outline the patient populations for which these regimens are intended, along with the dosages, schedules, and routes of administration.

Career Highlights

Throughout his career, Thomas P. Cirrito has worked with prominent companies in the biotechnology sector. Notable among these are Stemline Therapeutics, Inc. and Immunovent, LLC. His experience in these organizations has contributed to his expertise in developing innovative cancer therapies.

Collaborations

Cirrito has collaborated with various professionals in the field, including Ivan Bergstein and Christopher Brooks. These partnerships have further enhanced his research and development efforts in cancer treatment.

Conclusion

Thomas P. Cirrito is a distinguished inventor whose work in cancer vaccine development is making a significant impact in the medical field. His innovative approaches and collaborations are essential in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…